Cell-free DNA mutations as biomarkers in breast cancer patients receiving tamoxifen

The aim was to identify mutations in serum cell-free DNA (cfDNA) associated with disease progression on tamoxifen treatment in metastatic breast cancer (MBC). Sera available at start of therapy, during therapy and at disease progression were selected from 10 estrogen receptor (ER)-positive breast ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Jansen, Maurice P.H.M., Martens, John W.M., Helmijr, Jean C.A., Beaufort, Corine M., van Marion, Ronald, Krol, Niels M.G., Monkhorst, Kim, Trapman-Jansen, Anita M.A.C., Meijer-van Gelder, Marion E., Weerts, Marjolein J.A., Ramirez-Ardila, Diana E., Jan Dubbink, Hendrikus, Foekens, John A., Sleijfer, Stefan, Berns, Els M.J.J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5190033/
https://www.ncbi.nlm.nih.gov/pubmed/27270325
http://dx.doi.org/10.18632/oncotarget.9727

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5190033/
https://www.ncbi.nlm.nih.gov/pubmed/27270325
http://dx.doi.org/10.18632/oncotarget.9727

Ejemplares similares